In reaction to strong earnings/guidance: CRMB +12.5%, MLHR +5.5%, BGMD +4.1% (light volume, also announces issuance of patent covering Galectin-3 testing for Cardiac Resynchronization Therapy), RGDX +3.4% (light volume), LEN +2.1%, TSL +1.6% (announces receipt of favorable arbitration award and adjusts fourth quarter and full year 2013 earnings results), CAG +1.4%, JBL +1%, SVA +1%, CTAS +0.7%.
Other news: SNTA +21.1% (announces positive interim results from the ENCHANT-1 trial of ganetespib in metastatic breast cancer at the 9th European Breast Cancer Conference; all objective responses were confirmed by independent radiological review), DCTH +11.4% (continued strength), NAVB +8% (provides update on European Marketing Authorization Application for Lymphoseek: 'Committee will continue with its review of the MAA'), MNGA +8% (selected for four demolition projects), GERN +7.5% (reports Myelofibrosis IST placed on partial clinical hold), TNGO +5.4% (still checking), AEG +2.5% (strength in overseas trading that was attributed to US rate outlook), MT +1.4% (still checking), VOYA +0.8% (prices 33.8 mln shares of common stock; upgraded to Buy from Hold at Deutsche Bank), FPRX +0.7% (discloses it entered into a Research Collaboration and License Agreement with Bristol-Myers Squibb), SUNE +0.6% (announces private placement of shares to Samsung in connection with SunEdison Semiconductor IPO), SGEN +0.6% (following positive MadMoney mention).
Analyst comments: REPH +7.2% (initiated with a Buy at Brean), ZIOP +3.1% ( initiated with a Buy at Mizuho), ZLTQ +2% ( initiated with a Buy at Stifel), ULTA +1.7% ( upgraded to Buy from Neutral at Goldman), YUM +0.3% (upgraded to Outperform from Mkt Perform at First Global)
News 
Market Data 
Discover 
AI
